IARS1

IARS1 encodes the cytoplasmic isoleucyl-tRNA synthetase, an enzyme whose aminoacylation activity charges tRNA with isoleucine; the catalytic essentiality of this function is established by the V79L variant reducing aminoacylation activity in vitro (PMID:23700453) and by wild-type human IARS1 rescuing growth of ILS-null yeast where the p.Asp249Gly disease variant fails to complement (PMID:40365325). Biallelic loss-of-function mutations cause a multisystem developmental disorder: zebrafish modeling of compound heterozygous variants recapitulates defects in embryonic, neuro-, liver, and muscle development (PMID:35668413). Beyond its canonical synthetase role, loss of IARS1 function drives mitochondrial dysfunction — knockdown in HepG2 cells lowers mitochondrial membrane potential and raises ROS (PMID:37108118), and a hypomorphic V79L knock-in mouse develops hepatic triglyceride accumulation and elevated serum ornithine carbamoyltransferase with reduced mitochondrial NME4 (PMID:37108118).

1. 2013 Medium

   Establishing whether a disease-associated residue is catalytically important required direct enzymatic testing; the V79L assay showed this residue is needed for the synthetase's aminoacylation activity.

   Evidence In vitro aminoacylation assay comparing mutant and wild-type IARS1 protein

   PMID:23700453

   Open questions at the time

   • Single residue tested; does not map the full catalytic or substrate-binding architecture
   • In vitro activity not linked to organismal phenotype in this study
2. 2022 Medium

   Whether human disease variants are loss-of-function and which tissues they affect was unresolved; zebrafish modeling of compound heterozygous variants showed loss of function recapitulating multi-organ developmental defects.

   Evidence Zebrafish embryo loss-of-function modeling of p.L234P and p.R519C with developmental, neuro, liver, and myogenic readouts

   PMID:35668413

   Open questions at the time

   • Does not resolve the molecular mechanism linking synthetase loss to each organ phenotype
   • Phenotypes in fish embryos may not map directly to human pathophysiology
3. 2023 Medium

   How cytoplasmic synthetase loss produces hepatopathy was unknown; cellular and in vivo work connected IARS1 loss to mitochondrial dysfunction.

   Evidence siRNA knockdown in HepG2 cells (membrane potential, ROS) and V79L knock-in mouse (hepatic triglyceride, serum OCT, NME4 proteomics)

   PMID:37108118

   Open questions at the time

   • Causal chain from reduced aminoacylation to mitochondrial membrane potential loss not defined
   • Role of decreased NME4 in the phenotype not functionally tested
   • Whether mitochondrial defect is secondary to global translational stress unresolved
4. 2025 Medium

   Whether the human Asp249Gly variant is truly loss-of-function needed an orthogonal functional test; yeast complementation confirmed it fails to support growth where wild-type rescues.

   Evidence Complementation of ILS-null yeast by wild-type versus mutant human IARS1

   PMID:40365325

   Open questions at the time

   • Binary growth readout does not quantify residual catalytic activity
   • Yeast context lacks human multisynthetase complex partners
5. 2025 Low

   How non-catalytic domain mutations cause disease was unclear; a UNE-L domain variant was shown to destabilize the protein and dysregulate the integrated stress response without altering bulk translation.

   Evidence Cell-based expression of mutant vs wild-type with western blot, protein synthesis and proliferation assays, and ISR analysis (preprint)

   PMID:bio_10.1101_2025.08.21.671621

   Open questions at the time

   • Preprint, single lab, not independently confirmed
   • Direct link between multisynthetase complex disruption and ISR activation not reconstituted
   • Glucose-dependent exacerbation mechanism undefined
6. 2026 Low

   Whether IARS1 deficiency drives an immune/clearance phenotype was open; patient PBMC analysis correlated biallelic mutations with monocyte/macrophage dysfunction.

   Evidence scRNA-seq of patient PBMCs, BALF staining, western blot, and electron microscopy

   PMID:42237414

   Open questions at the time

   • Observational and correlative; no functional rescue or mechanistic reconstitution
   • Intrinsic vs systemic origin of the monocyte defect not established
   • Link to synthetase catalytic loss not demonstrated

• The mechanistic bridge between reduced isoleucine aminoacylation, multisynthetase complex integrity, integrated stress response activation, and the tissue-specific phenotypes (liver, mitochondria, monocytes, neurodevelopment) remains undefined.
• No structural model of IARS1 catalytic or UNE-L domains in the corpus
• Whether mitochondrial and immune phenotypes are downstream of the same translational defect unknown
• Quantitative genotype-to-residual-activity-to-severity relationship not mapped